Verastem Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial

Reuters

2025/10/24

<a href="https://laohu8.com/S/VSTM">Verastem</a> Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial

Verastem Inc. has announced encouraging preliminary data from its ongoing Phase 1/2a clinical trial evaluating VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with previously-treated advanced KRAS G12D mutant solid tumors. The first two monotherapy dose levels (400 mg QD and 600 mg QD) have been cleared with no dose-limiting toxicities reported, and promising anti-tumor activity has been observed across various solid tumors, including advanced pancreatic ductal adenocarcinoma. Gastrointestinal tolerability has been favorable, with no nausea, vomiting, or diarrhea greater than Grade 1 observed. Patient enrollment has also begun for the first dose escalation combination cohort of VS-7375 with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer. Verastem plans to report an interim safety and efficacy update on the Phase 1/2a trial in the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023370473) on October 23, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2577533008"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577533008\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577533008?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577533008","market":"fut","top_or_hot":-1,"title":"Verastem Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Verastem Inc. has announced encouraging preliminary data from its ongoing Phase 1/2a clinical trial evaluating VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with previously-treated advanced KRAS G12D mutant solid tumors. The first two monotherapy dose levels (400 mg QD and 600 mg QD) have been cleared with no dose-limiting toxicities reported, and promising anti-tumor activity has been observed across various solid tumors, including advanced pancreatic ductal adenocarcinoma. Gastrointestinal tolerability has been favorable, with no nausea, vomiting, or diarrhea greater than Grade 1 observed. Patient enrollment has also begun for the first dose escalation combination cohort of VS-7375 with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer. Verastem plans to report an interim safety and efficacy update on the Phase 1/2a trial in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023370473) on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-24 04:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Verastem Inc. has announced encouraging preliminary data from its ongoing Phase 1/2a clinical trial evaluating VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with previously-treated advanced KRAS G12D mutant solid tumors. The first two monotherapy dose levels (400 mg QD and 600 mg QD) have been cleared with no dose-limiting toxicities reported, and promising anti-tumor activity has been observed across various solid tumors, including advanced pancreatic ductal adenocarcinoma. Gastrointestinal tolerability has been favorable, with no nausea, vomiting, or diarrhea greater than Grade 1 observed. Patient enrollment has also begun for the first dose escalation combination cohort of VS-7375 with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer. Verastem plans to report an interim safety and efficacy update on the Phase 1/2a trial in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023370473) on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL7tcJFP:1","article_id":"2577533008","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577533008","pubTimestamp":1761249688,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Verastem Inc. has announced encouraging preliminary data from its ongoing Phase 1/2a clinical trial evaluating VS-7375, an oral KRAS G12D  inhibitor, in patients with previously-treated advanced KRAS G12D mutant solid tumors. The first two monotherapy dose levels  have been cleared with no dose-limiting toxicities reported, and promising anti-tumor activity has been observed across various solid tumors, including advanced pancreatic ductal adenocarcinoma. Gastrointestinal tolerability has been favorable, with no nausea, vomiting, or diarrhea greater than Grade 1 observed. Patient enrollment has also begun for the first dose escalation combination cohort of VS-7375 with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer. Verastem plans to report an interim safety and efficacy update on the Phase 1/2a trial in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VSTM":"Verastem"},"translate_title":"Verastem报告KRAS G12D抑制剂在正在进行的1/2a期试验中取得令人鼓舞的早期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":0.9},"content_text":"Verastem Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial\n    \n\n        Verastem Inc. has announced encouraging preliminary data from its ongoing Phase 1/2a clinical trial evaluating VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with previously-treated advanced KRAS G12D mutant solid tumors. The first two monotherapy dose levels (400 mg QD and 600 mg QD) have been cleared with no dose-limiting toxicities reported, and promising anti-tumor activity has been observed across various solid tumors, including advanced pancreatic ductal adenocarcinoma. Gastrointestinal tolerability has been favorable, with no nausea, vomiting, or diarrhea greater than Grade 1 observed. Patient enrollment has also begun for the first dose escalation combination cohort of VS-7375 with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer. Verastem plans to report an interim safety and efficacy update on the Phase 1/2a trial in the first half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023370473) on October 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}